suramin has been researched along with Disease Exacerbation in 11 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)." | 9.09 | Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001) |
| "We recently showed that suramin treatment prevents the onset of renal fibrosis in a model of obstructive nephropathy induced by unilateral ureteral obstruction (UUO)." | 7.77 | Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. ( Liu, N; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011) |
| "Suramin is a compound that inhibits the interaction of several cytokines and growth factors with their receptors, but whether suramin inhibits the progression of renal fibrosis is unknown." | 5.37 | Suramin inhibits renal fibrosis in chronic kidney disease. ( Liu, N; Pang, M; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011) |
| "Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =." | 5.09 | Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. ( Chen, L; Eisenberger, M; Lenehan, PF; Marshall, ME; Meyer, M; Meyers, FJ; Natale, RB; Reyno, LM; Slichenmyer, WJ; Small, EJ, 2000) |
| "Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)." | 5.09 | Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001) |
| "We recently showed that suramin treatment prevents the onset of renal fibrosis in a model of obstructive nephropathy induced by unilateral ureteral obstruction (UUO)." | 3.77 | Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. ( Liu, N; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011) |
| "Suramin was administered on a 78-day fixed dosing schedule (one cycle), and suramin treatment cycles were repeated every 6 months for a total of four cycles." | 2.69 | Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. ( Crawford, ED; Eisenberger, MA; Fisher, EI; Hussain, M; O'Connor, J; Petrylak, DP; Small, EJ; Wood, DP, 2000) |
| "Patients with stage D2 and poor-prognosis stage D1 prostate cancer were given suramin on a pharmacokinetically derived dosing schedule to maintain suramin concentrations between 175 and 300 micrograms/mL." | 2.68 | Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. ( Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Myers, CE; Reed, E; Sartor, O; Sausville, EA; Senderowicz, AM; Steinberg, SM; Tompkins, A; Weinberger, B, 1997) |
| "Suramin was also effective in blocking CG-induced phosphorylation of inhibitor of κB (IκB) and nuclear factor (NF)-κBp65, expression of several inflammatory cytokines, and infiltration of macrophages in the peritoneum." | 1.40 | Suramin inhibits the development and progression of peritoneal fibrosis. ( Fang, L; Liu, N; Xiong, C; Yan, H; Zhuang, S, 2014) |
| "Suramin is a compound that inhibits the interaction of several cytokines and growth factors with their receptors, but whether suramin inhibits the progression of renal fibrosis is unknown." | 1.37 | Suramin inhibits renal fibrosis in chronic kidney disease. ( Liu, N; Pang, M; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011) |
| "No significant difference in time to disease progression or survival was observed between African Americans (n = 4) and the other 39 patients." | 1.30 | Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer. ( Bergan, RC; Dawson, NA; Figg, WD; Headlee, D; Reed, E; Steinberg, SM; Tompkins, A; Walls, RG, 1997) |
| "Metastatic prostate cancer is a growing health problem and is the second leading cause of cancer death in men." | 1.30 | Management of progressive metastatic prostate cancer. ( Dawson, NA; Waselenko, JK, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xiong, C | 1 |
| Liu, N | 3 |
| Fang, L | 1 |
| Zhuang, S | 3 |
| Yan, H | 3 |
| Tolbert, E | 2 |
| Pang, M | 1 |
| Ponnusamy, M | 2 |
| Richter, J | 1 |
| Göbels, S | 1 |
| Göbel, T | 1 |
| Westenfeld, R | 1 |
| Müller-Stöver, I | 1 |
| Häussinger, D | 1 |
| Song, S | 1 |
| Yu, B | 1 |
| Wei, Y | 1 |
| Wientjes, MG | 1 |
| Au, JL | 1 |
| Dawson, NA | 3 |
| Figg, WD | 2 |
| Cooper, MR | 1 |
| Sartor, O | 1 |
| Bergan, RC | 2 |
| Senderowicz, AM | 1 |
| Steinberg, SM | 2 |
| Tompkins, A | 2 |
| Weinberger, B | 1 |
| Sausville, EA | 1 |
| Reed, E | 2 |
| Myers, CE | 1 |
| Walls, RG | 1 |
| Headlee, D | 1 |
| Waselenko, JK | 1 |
| Hussain, M | 1 |
| Fisher, EI | 1 |
| Petrylak, DP | 1 |
| O'Connor, J | 1 |
| Wood, DP | 1 |
| Small, EJ | 2 |
| Eisenberger, MA | 1 |
| Crawford, ED | 1 |
| Meyer, M | 1 |
| Marshall, ME | 1 |
| Reyno, LM | 1 |
| Meyers, FJ | 1 |
| Natale, RB | 1 |
| Lenehan, PF | 1 |
| Chen, L | 1 |
| Slichenmyer, WJ | 1 |
| Eisenberger, M | 1 |
| Calvo, E | 1 |
| Cortés, J | 1 |
| Rodríguez, J | 1 |
| Sureda, M | 1 |
| Beltrán, C | 1 |
| Rebollo, J | 1 |
| Martínez-Monge, R | 1 |
| Berián, JM | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336] | Phase 2 | 1 participants (Actual) | Interventional | 2017-01-06 | Terminated (stopped due to can not meet enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Calcitriol, Ketoconazole, Hydrocortisone | 1 |
4 trials available for suramin and Disease Exacerbation
| Article | Year |
|---|---|
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diseas | 1997 |
Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Topics: Adult; Aged; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc | 2000 |
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dise | 2000 |
Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progress | 2001 |
7 other studies available for suramin and Disease Exacerbation
| Article | Year |
|---|---|
Suramin inhibits the development and progression of peritoneal fibrosis.
Topics: Actins; Angiogenesis Inducing Agents; Animals; Collagen Type I; Cytokines; Disease Models, Animal; D | 2014 |
Suramin inhibits renal fibrosis in chronic kidney disease.
Topics: Actins; Animals; Antineoplastic Agents; Cells, Cultured; Chronic Disease; Disease Models, Animal; Di | 2011 |
Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy.
Topics: Actins; Animals; Blotting, Western; Cells, Cultured; Collagen Type I; Disease Progression; ErbB Rece | 2011 |
A returning traveller with fever, facial swelling, and skin lesions.
Topics: Adrenal Cortex Hormones; Animals; Diagnosis, Differential; Disease Progression; Face; Fever; Humans; | 2012 |
Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Black People; Disease Progression; Humans; Male; Mid | 1997 |
Management of progressive metastatic prostate cancer.
Topics: Androgen Antagonists; Androgens; Diphosphonates; Disease Progression; Hormones; Humans; Male; Prosta | 1997 |